Ligand Pharmaceuticals Incorporated [LGND]

John L. Higgins, President and CEO of Ligand Pharmaceuticals Incorporated, presides over the opening bell.

Wednesday September 26, 2007
from Nasdaq MarketSite
in New York's Times Square

Ligand Pharmaceuticals Incorporated
[LGND]

Additional Photographs & Reprint Permissions
Archived MarketSite Events | Summary Quote

John L. Higgins, President and CEO of Ligand Pharmaceuticals Incorporated (LGND), along with the executive management team and Board of Directors, preside over the opening bell.

Ligand discovers and develops new drugs that address critical unmet medical needs of patients in the areas of thrombocytopenia, hepatitis C, cancer, hormone-related diseases, osteoporosis and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

Reprints

Click for larger pictures of the NASDAQ MarketSite.

Additional Photographs for 09/26/2007

Download Hi-Res Quality Photo of this NASDAQ Market Open
- Pictured: John L. Higgins, President and CEO of Ligand Pharmaceuticals Incorporated, presides over the opening bell.
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at Jolene.Libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission.